HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.

Lancet
Authors
Abstract

Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target.

Year of Publication
2014
Journal
Lancet
Date Published
2014/09/24
ISSN
0140-6736
DOI
10.1016/S0140-6736(14)61183-1
PubMed ID
25262344
PubMed Central ID
PMC4322187
Links